Our organization has recently undergone a transformation, evolving from an international analysis laboratory network into a network of investigation sites under the responsibility of our medical biologists. We now include patients in non-interventional clinical and observational studies through digital means, expanding our services to a variety of industries, including pharma, biotech, institutional, medical device, and diagnostic clients. From 2020 to 2022, we successfully enrolled over 7,500 participants in pre and post-market clinical trials.

Building on this success, we continue to diversify our offerings in new diagnostic and therapeutic areas and develop private and public partnerships in France and in Africa. Our procedures are adapted to each region’s unique legislation to ensure compliance. As a new type of CRO, we offer tailored services that meet the demands of our customers as either sponsor or investigator, depending on the study.